DUBLIN, Mar 21, 2017 /PRNewswire/ --
Research and Markets has announced the addition of the "Global Epinephrine Autoinjector Market 2017-2021" report to their offering.
The global epinephrine autoinjector market to grow at a CAGR of 14.58% during the period 2017-2021.
The report, Global Epinephrine Autoinjector Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the Key vendors operating in this market.
The latest trend gaining momentum in the market is tentative product launches. The US market is forecasted to witness a number of product launches during the forecast period, due to the increased government's pressure on the FDA to approve more generic products of epinephrine autoinjectors.
According to the report, one of the major drivers for this market is increasing prevalence of allergies. The prevalence of allergies to food items, food additives, latex, and dust and the associated anaphylaxis has been increasing worldwide. On average, 30-35% of the global population is diagnosed with an allergy annually. This was initially seen in countries such as the UK, other countries in Europe, and the US, but it is now common in all industrially developed countries.
Further, the report states that one of the major factors hindering the growth of this market is product recalls and regulatory issues. The global epinephrine autoinjector market has continuously faced hindrance owing to the periodic product recalls and regulatory issues over the years. The FDA approval process for epinephrine autoinjectors also has been slow, which paved the way for Mylan monopoly.
- Impax Laboratories
- Lincoln Medical
Other prominent vendors:
- Adamis Pharmaceuticals
- Antares Pharma
- Kaleo Pharma
- Teva Pharmaceutical Industries
Key Topics Covered:
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Market research methodology
PART 04: Introduction
PART 05: Market landscape
PART 06: Market segmentation by dosage
PART 07: Market segmentation by age group
PART 08: Market segmentation by end-user
PART 09: Geographical segmentation
PART 10: Market drivers
PART 11: Impact of drivers
PART 12: Market challenges
PART 13: Impact of drivers and challenges
PART 14: Market trends
PART 15: Vendor landscape
PART 16: Key vendor analysis
For more information about this report visit http://www.researchandmarkets.com/research/nqhdl4/global
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-epinephrine-autoinjector-market-2017-2021---by-dosage-age-group--end-user---research-and-markets-300426935.html
SOURCE Research and Markets